187 related articles for article (PubMed ID: 14628077)
21. Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
Kobayashi K; Kami M; Murashige N; Kusumi E; Kishi Y; Hamaki T; Hori A; Matsumura T; Yuji K; Masuo S; Mori S; Miyakoshi S; Tanosaki R; Mitamura T; Takaue Y; Taniguchi S;
Br J Haematol; 2005 Jun; 129(6):795-802. PubMed ID: 15953007
[TBL] [Abstract][Full Text] [Related]
22. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
23. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
[TBL] [Abstract][Full Text] [Related]
26. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children.
Bader P; Klingebiel T; Schaudt A; Theurer-Mainka U; Handgretinger R; Lang P; Niethammer D; Beck JF
Leukemia; 1999 Dec; 13(12):2079-86. PubMed ID: 10602432
[TBL] [Abstract][Full Text] [Related]
27. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
28. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
[TBL] [Abstract][Full Text] [Related]
29. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
Massenkeil G; Nagy M; Lawang M; Rosen O; Genvresse I; Geserick G; Dörken B; Arnold R
Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
[TBL] [Abstract][Full Text] [Related]
30. Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?
Bader P; Beck J; Schlegel PG; Handgretinger R; Niethammer D; Klingebiel T
Bone Marrow Transplant; 1997 Jul; 20(1):79-81. PubMed ID: 9232263
[TBL] [Abstract][Full Text] [Related]
31. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study.
Lanino E; Rondelli R; Locatelli F; Messina C; Pession A; Balduzzi A; Favre C; Santarone S; Rabusin M; Pollichieni S; Cesaro S; Dini G;
Biol Blood Marrow Transplant; 2009 Jun; 15(6):741-8. PubMed ID: 19450759
[TBL] [Abstract][Full Text] [Related]
32. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
[TBL] [Abstract][Full Text] [Related]
34. [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].
Kuroki F; Goto H; Yanagimachi M; Kajiwara R; Fujii H; Isaki S; Takahashi H; Ikuta K; Yokota S
Rinsho Ketsueki; 2006 Jul; 47(7):639-44. PubMed ID: 16910574
[TBL] [Abstract][Full Text] [Related]
35. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
36. Monitoring of donor cell chimerism for the detection of relapse and early immunotherapeutic intervention in acute lymphoblastic leukemias.
Bader P; Dückers G; Kreyenberg H; Hoelle W; Kerst G; Lang P; Greil J; Niethammer D; Beck LF; Klingebiel T
Ann Hematol; 2002; 81 Suppl 2():S25-7. PubMed ID: 12611064
[No Abstract] [Full Text] [Related]
37. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
38. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
[TBL] [Abstract][Full Text] [Related]
39. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
40. [Donor peripheral hematopoietic stem cells infusion for prophylaxis of relapse of high risk leukemia after allogeneic hematopoietic stem cell transplantation].
Liu DH; Huang XJ; Chen H; Xu LP; Liu KY; Han W; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):6-9. PubMed ID: 16732930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
